NIAID to begin HVTN 702 study of new HIV vaccine regimen in South Africa

The National Institute of Allergy and Infectious Diseases (NIAID) is set to initiate a new research study, HVTN 702, of a new HIV vaccine in South Africa.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news